ARQT logoARQT
Arcutis Biotherapeutics Inc

2,454
Loading...
Loading...
News
all
press releases
Arcutis Biotherapeutics, Inc. (ARQT) Hit a 52 Week High, Can the Run Continue?
Arcutis Biotherapeutics (ARQT) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Zacks·2d ago
News Placeholder
More News
News Placeholder
Are Medical Stocks Lagging Arcutis Biotherapeutics (ARQT) This Year?
Here is how Arcutis Biotherapeutics, Inc. (ARQT) and Cardinal Health (CAH) have performed compared to their sector so far this year.
Zacks·4d ago
News Placeholder
Here's Why Arcutis Biotherapeutics, Inc. (ARQT) is a Great Momentum Stock to Buy
Does Arcutis Biotherapeutics, Inc. (ARQT) have what it takes to be a top stock pick for momentum investors? Let's find out.
Zacks·8d ago
News Placeholder
Are Medical Stocks Lagging AxoGen (AXGN) This Year?
Here is how AxoGen (AXGN) and Arcutis Biotherapeutics, Inc. (ARQT) have performed compared to their sector so far this year.
Zacks·21d ago
News Placeholder
Does Arcutis Biotherapeutics (ARQT) Have the Potential to Rally 45.81% as Wall Street Analysts Expect?
The average of price targets set by Wall Street analysts indicates a potential upside of 45.8% in Arcutis Biotherapeutics (ARQT). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Zacks·1mo ago
News Placeholder
Is Arcutis Biotherapeutics (ARQT) Stock Outpacing Its Medical Peers This Year?
Here is how Arcutis Biotherapeutics, Inc. (ARQT) and Foghorn Therapeutics Inc. (FHTX) have performed compared to their sector so far this year.
Zacks·1mo ago
News Placeholder
Wall Street Analysts Predict a 44.79% Upside in Arcutis Biotherapeutics (ARQT): Here's What You Should Know
The average of price targets set by Wall Street analysts indicates a potential upside of 44.8% in Arcutis Biotherapeutics (ARQT). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Zacks·2mo ago
News Placeholder
Are Medical Stocks Lagging Arcutis Biotherapeutics (ARQT) This Year?
Here is how Arcutis Biotherapeutics, Inc. (ARQT) and Tenet Healthcare (THC) have performed compared to their sector so far this year.
Zacks·2mo ago
News Placeholder
Arcutis Biotherapeutics, Inc. (ARQT) Reports Q2 Loss, Beats Revenue Estimates
Arcutis Biotherapeutics (ARQT) delivered earnings and revenue surprises of +27.78% and +12.32%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·2mo ago
News Placeholder
Arcutis Biotherapeutics, Inc. (ARQT) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
Arcutis Biotherapeutics (ARQT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zacks·2mo ago

Latest ARQT News

View

Advertisement|Remove ads.

Advertisement|Remove ads.